Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
University of Kansas
ClinicalTrials.gov Identifier:
NCT00000217
First received: September 20, 1999
Last updated: June 12, 2013
Last verified: June 2013
  Purpose

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Drug: Carbamazepine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacotherapy and Intensive Treatment of Drug Abuse

Resource links provided by NLM:


Further study details as provided by University of Kansas:

Primary Outcome Measures:
  • Drug use
  • Effectiveness of medication
  • Level of pharm
  • Retention
  • Depression, anxiety

Study Start Date: September 1990
Primary Completion Date: October 1996 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000217

Locations
United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128
Sponsors and Collaborators
University of Kansas
Investigators
Principal Investigator: William Haning, M.D. University of Kansas
  More Information

No publications provided

Responsible Party: University of Kansas
ClinicalTrials.gov Identifier: NCT00000217     History of Changes
Other Study ID Numbers: NIDA-06954-1, R18DA006954, R18-06954-1
Study First Received: September 20, 1999
Last Updated: June 12, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Disease
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Pathologic Processes
Carbamazepine
Analgesics
Analgesics, Non-Narcotic
Anticonvulsants
Antimanic Agents
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on October 20, 2014